Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Stopped This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.

Conditions

Recurrent Platinum Resistant Epithelial Ovarian Carcinoma
Recurrent Epithelial Endometrial Carcinoma
Recurrent Epithelial Cervical Carcinoma

Interventions

DRUG: Sacituzumab Govitecan
DIAGNOSTIC_TEST: EKG
DIAGNOSTIC_TEST: Brain MRI
DIAGNOSTIC_TEST: CT scans
PROCEDURE: Tumor biopsy
DRUG: Loperamide
DRUG: Octreotide
DRUG: Diphenoxylate/Atropine
DRUG: Antiemetics

Sponsor

National Cancer Institute (NCI)